IVF$1.84+0.55%
INVO Fertility, Inc.
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Mkt Cap:$2.12M
Float & O/S:
Inst Own:
DilutionScan read 36 of INVO Fertility, Inc.'s SEC filings and found 12 warrant series, 6 convertibles, 1 equity line, 1 shelf registration, 5 S-1 registrations and 3 completed offerings on file for IVF. The latest dilution event on file is a registration statement on Aug 4, 2026. Analysis updated Nov 1, 2026.
Signal8 Summary
IVF
Going-concern warning, triple reverse splits
- Business
- WeakNet loss $23.3M on $6.8M revenue, going-concern language
- Stock risk
- High3 reverse splits in 12 months, 89.7% dilution registered
Snapshot
INVO is a tiny fertility-clinic operator with FY 2025 revenue of $6.8M, up modestly, but a net loss of $23.3M that dwarfs the entire top line.
What's Happening Right Now
- : INVO completed a 1-for-4 reverse stock split effective Oct 30, 2026, its third such split in the last 12 months, leaving roughly 1.19 million shares outstanding.
- : INVO's Wisconsin Fertility Institute presented five posters on platelet-rich plasma treatment outcomes at the 2026 Midwest Reproductive Symposium International.
- : INVO reported Q2 2026 revenue up 17% to $2.18 million and a $0.9 million net profit (driven by a non-cash acquisition gain), with the clinic platform itself profitable on an adjusted basis before corporate overhead.
- : INVO's Q2 2026 10-Q disclosed explicit going-concern language, with cash of $3.73 million against about $3.0 million of first-half operating cash burn and reliance on further debt or equity raises.
- : INVO filed a prospectus registering up to 20 million shares for resale by Alumni Capital under a purchase agreement that could bring in up to $15 million (expandable to $50 million), with the registered shares representing about 89.7% of shares outstanding and purchases priced at discounts of 85-97% to market.
